Neuroprotective activities of CEP-1347 in models of neuroAIDS

Journal of Immunology

Volumn 184, Issue 2, 2010, Pages 746-756

  Eggert, Dawn ^a   Dash, Prasanta K ^a   Gorantla, Santhi ^a   Dou, Huanyu ^a   Schifitto, Giovanni ^b   Maggirwar, Sanjay B ^b   Dewhurst, Stephen ^b   Poluektova, Larisa ^a   Gelbard, Harris A ^b   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 1347; 3,9 BIS((ETHYLTHIO)METHYL) K 252A; 3,9-BIS((ETHYLTHIO)METHYL)-K-252A; CARBAZOLE DERIVATIVE; CYTOKINE; NEUROPROTECTIVE AGENT; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN DISEASE; BRAIN NERVE CELL; CELL ACTIVATION; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITE; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; EMBRYO; HIV 1 ASSOCIATED NEUROCOGNITIVE DISORDER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MACROPHAGE; MALE; MICROGLIA; MONOCYTE; MONONUCLEAR PHAGOCYTE; MOUSE; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCID MOUSE; ADJUVANT CHEMOTHERAPY; ANIMAL; DRUG EFFECT; GLIOSIS; HIV ASSOCIATED DEMENTIA; INFLAMMATION; PATHOLOGY; SECRETION; TREATMENT OUTCOME; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANIMALS; BASAL GANGLIA; CARBAZOLES; CEREBRAL CORTEX; CHEMOTHERAPY, ADJUVANT; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOSIS; HUMANS; INFLAMMATION; MACROPHAGES; MICE; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 76249099852     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902962     Document Type: Article

References (86)

1. Lipton, S. A., and H. E. Gendelman. 1995. Dementia associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 332: 934-940.
2. Michaels, J., L. R. Sharer, and L. G. Epstein. 1988. Human immunodeficiency virus type 1 (HIV-1) infection of the nervous system: a review. Immunodefic. Rev. 1: 71-104.
3. Everall, I. P., P. J. Luthert, and P. L. Lantos. 1991. Neuronal loss in the frontal cortex in HIV infection. [see comments] Lancet 337: 1119-1121.
4. Swindells, S., J. Zheng, and H. E. Gendelman. 1999. HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions. AIDS Patient Care STDS 13: 153-163. (Pubitemid 29155983)
5. Kure, K., J. F. Llena, W. D. Lyman, R. Soeiro, K. M. Weidenheim, A. Hirano, and D. W. Dickson. 1991. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum. Pathol. 22: 700-710.
6. An, S. F., and F. Scaravilli. 1997. Early HIV-1 infection of the central nervous system. Arch. Anat. Cytol. Pathol. 45: 94-105.
7. Villa, G., A. Solida, E. Moro, M. Tavolozza, A. Antinori, A. De Luca, R. Murri, and E. Tamburrini. 1996. Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur. Neurol. 36: 125-133.
8. Antinori, A., G. Arendt, J. T. Becker, B. J. Brew, D. A. Byrd, M. Cherner, D. B. Clifford, P. Cinque, L. G. Epstein, K. Goodkin, et al. 2007. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799.
9. Letendre, S., B. Ances, S. Gibson, and R. J. Ellis. 2007. Neurologic complications of HIV disease and their treatment. Top. HIV Med. 15: 32-39.
10. Masliah, E., N. Ge, C. L. Achim, R. DeTeresa, and C. A. Wiley. 1996. Patterns of neurodegeneration in HIV encephalitis. NeuroAIDS 1: 161-173.
11. Anderson, E., W. Zink, H. Xiong, and H. E. Gendelman. 2002. HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J. Acquir. Immune Defic. Syndr. 31 (Suppl 2): S43-S54.
12. Nukuna, A., H. E. Gendelman, J. Limoges, J. Rasmussen, L. Poluektova, A. Ghorpade, and Y. Persidsky. 2004. Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. J. Neurovirol. 10(Suppl 1): 82-90.
13. Nottet, H. S., and H. E. Gendelman. 1995. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol. Today 16: 441-448.
14. Nath, A., and J. Geiger. 1998. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog. Neurobiol. 54: 19-33.
15. Heyes, M. P., C. L. Achim, C. A. Wiley, E. O. Major, K. Saito, and S. P. Markey. 1996. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320: 595-597.
16. Perry, S. W., J. P. Norman, and H. A. Gelbard. 2005. Adjunctive therapies for HIV-1 associated neurologic disease. Neurotox. Res. 8: 161-166.
17. Schifitto, G., D. R. Peterson, J. Zhong, H. Ni, K. Cruttenden, M. Gaugh, H. E. Gendelman, M. Boska, and H. Gelbard. 2006. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66: 919-921.
18. Schifitto, G., C. T. Yiannoutsos, D. M. Simpson, C. M. Marra, E. J. Singer, D. L. Kolson, A. Nath, J. R. Berger, and B. Navia; Adult AIDS Clinical Trials Group (ACTG) 301 tEAM. 2006. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J. Neurovirol. 12: 328-331.
19. Schifitto, G., N. Sacktor, K. Marder, M. P. McDermott, J. C. McArthur, K. Kieburtz, S. Small, and L. G. Epstein; Neurological AIDS Research Consortium. 1999. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurology 53: 391-396.
20. Tözsér, J. 2001. HIV inhibitors: problems and reality. Ann. N. Y. Acad. Sci. 946: 145-159.
21. Deeks, S. G., R. Hoh, T. B. Neilands, T. Liegler, F. Aweeka, C. J. Petropoulos, R. M. Grant, and J. N. Martin. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192: 1537-1544.
22. Cunningham, P. H., D. G. Smith, C. Satchell, D. A. Cooper, and B. Brew. 2000. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 14: 1949-1954.
23. Sacktor, N., R. H. Lyles, R. Skolasky, C. Kleeberger, O. A. Selnes, E. N. Miller, J. T. Becker, B. Cohen, and J. C. McArthur; Multicenter AIDS Cohort Study. 2001. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56: 257-260.
24. Dore, G. J., P. K. Correll, Y. Li, J. M. Kaldor, D. A. Cooper, and B. J. Brew. 1999. Changes to AIDS dementia complex in the era of highly active anti-retroviral therapy. AIDS 13: 1249-1253.
25. Gebo, K. A. 2006. HIV and aging: implications for patient management. Drugs Aging 23: 897-913.
26. Gendelman, H. E. S. Diesing, H. Gelbard, and S. Swindells. 2004. The Neuropathogenesis of HIV-1 Infection. Elsevier, London.
27. Bellizzi, M. J., S. M. Lu, and H. A. Gelbard. 2006. Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. J. Neuroimmune Pharmacol. 1: 20-31.
28. Dewhurst, S., S. B. Maggirwar, G. Schifitto, H. E. Gendelman, and H. A. Gelbard. 2007. Glycogen synthase kinase 3 β (GSK-3 β) as a therapeutic target in neuroAIDS. J. Neuroimmune Pharmacol. 2: 93-96.
29. Gorantla, S., J. Liu, T. Wang, A. Holguin, H. M. Sneller, H. Dou, J. Kipnis, L. Poluektova, and H. E. Gendelman. 2008. Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis. Glia 56: 223-232.
30. Potula, R., L. Poluektova, B. Knipe, J. Chrastil, D. Heilman, H. Dou, O. Takikawa, D. H. Munn, H. E. Gendelman, and Y. Persidsky. 2005. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 106: 2382-2390.
31. Dou, H., B. Ellison, J. Bradley, A. Kasiyanov, L. Y. Poluektova, H. Xiong, S. Maggirwar, S. Dewhurst, H. A. Gelbard, and H. E. Gendelman. 2005. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J. Neurosci. 25: 8375-8385.
32. Wang, L. H., A. J. Paden, and E. M. Johnson, Jr. 2005. Mixed-lineage kinase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival. J. Pharmacol. Exp. Ther. 312: 1007-1019.
33. Bogoyevitch, M. A., I. Boehm, A. Oakley, A. J. Ketterman, and R. K. Barr. 2004. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 1697: 89-101.
34. Bozyczko-Coyne, D., T. M. O'Kane, Z. L. Wu, P. Dobrzanski, S. Murthy, J. L. Vaught, and R. W. Scott. 2001. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J. Neurochem. 77: 849-863.
35. Namgung, U., and Z. Xia. 2000. Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase 3 and p38 mitogen-activated protein kinase. J. Neurosci. 20: 6442-6451.
36. Waetzig, V., K. Czeloth, U. Hidding, K. Mielke, M. Kanzow, S. Brecht, M. Goetz, R. Lucius, T. Herdegen, and U. K. Hanisch. 2005. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 50: 235-246.
37. Lund, S., P. Porzgen, A. L. Mortensen, H. Hasseldam, D. Bozyczko-Coyne, S. Morath, T. Hartung, M. Bianchi, P. Ghezzi, M. Bsibsi, et al. 2005. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J. Neurochem. 92: 1439-1451.
38. Bodner, A., A. C. Maroney, J. P. Finn, G. Ghadge, R. Roos, and R. J. Miller. 2002. Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity. J. Neurochem. 82: 1424-1434.
39. Sui, Z., S. Fan, L. Sniderhan, E. Reisinger, A. Litzburg, G. Schifitto, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar. 2006. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J. Immunol. 177: 702-711. (Pubitemid 43939185)
40. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phipps, L. A. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167: 1428-1441.
41. Kalter, D. C., M. Nakamura, J. A. Turpin, L. M. Baca, D. L. Hoover, C. Dieffenbach, P. Ralph, H. E. Gendelman, and M. S. Meltzer. 1991. Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J. Immunol. 146: 298-306.
42. Zheng, J., A. Ghorpade, D. Niemann, R. L. Cotter, M. R. Thylin, L. Epstein, J. M. Swartz, R. B. Shepard, X. Liu, A. Nukuna, and H. E. Gendelman. 1999. Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia. J. Virol. 73: 8256-8267.
43. Morgan, D. M. 1998. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol. Biol. 79: 179-183.
44. Persidsky, Y., J. Limoges, R. McComb, P. Bock, T. Baldwin, W. Tyor, A. Patil, H. S. Nottet, L. Epstein, H. Gelbard, et al. 1996. Human immunodeficiency virus encephalitis in SCID mice. Am. J. Pathol. 149: 1027-1053.
45. Poluektova, L., S. Gorantla, J. Faraci, K. Birusingh, H. Dou, and H. E. Gendelman. 2004. Neuroregulatory events follow adaptive immunemediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J. Immunol. 172: 7610-7617. (Pubitemid 38747625)
46. Persidsky, Y., M. Buttini, J. Limoges, P. Bock, and H. E. Gendelman. 1997. An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. J. Neurovirol. 3: 401-416. (Pubitemid 28041140)
47. Gallo, K. A., and G. L. Johnson. 2002. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3: 663-672.
48. Roux, P. P., G. Dorval, M. Boudreau, A. Angers-Loustau, S. J. Morris, J. Makkerh, and P. A. Barker. 2002. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J. Biol. Chem. 277: 49473-49480.
49. Dore, G. J., J. F. Hoy, S. A. Mallal, Y. Li, A. M. Mijch, M. A. French, D. A. Cooper, and J. M. Kaldor. 1997. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16: 39-43.
50. Enting, R. H., R. M. Hoetelmans, J. M. Lange, D. M. Burger, J. H. Beijnen, and P. Portegies. 1998. Antiretroviral drugs and the central nervous system. AIDS 12: 1941-1955. (Pubitemid 28479270)
51. Clifford, D. B. 2000. Human immunodeficiency virus-associated dementia. Arch. Neurol. 57: 321-324.
52. Lipton, S. A. 1997. Treating AIDS dementia. Science 276: 1629-1630.
53. Major, E. O., D. Rausch, C. Marra, and D. Clifford. 2000. HIV-associated dementia. Science 288: 440-442.
54. Ferrando, S., W. van Gorp, M. McElhiney, K. Goggin, M. Sewell, and J. Rabkin. 1998. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 12: F65-F70.
55. Lipton, S. A., and H. E. Gendelman. 1995. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 332: 934-940.
56. Kaul, M., G. A. Garden, and S. A. Lipton. 2001. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988-994.
57. Gartner, S. 2000. HIV infection and dementia. Science 287: 602-604.
58. Lipton, S., and K. Kieburtz. 1998. Prospects for neuropharmacological intervention in AIDS dementia. In The Neurology of AIDS. H. Gendelman, S. Lipton, L. Epstein, and S. Swindells, eds. Chapman-Hall, N Y., pp. 377-381.
59. Lipton, S. A. 1998. Neuronal injury associated with HIV-1: approaches to treatment. Annu. Rev. Pharmacol. Toxicol. 38: 159-177.
60. Navia, B. A., U. Dafni, D. Simpson, T. Tucker, E. Singer, J. C. McArthur, C. Yiannoutsos, L. Zaborski, and S. A. Lipton. 1998. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 51: 221-228.
61. Maroney, A. C., J. P. Finn, T. J. Connors, J. T. Durkin, T. Angeles, G. Gessner, Z. Xu, S. L. Meyer, M. J. Savage, L. A. Greene, et al. 2001. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276: 25302-25308.
62. Silva, R. M., C. Y. Kuan, P. Rakic, and R. E. Burke. 2005. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov. Disord. 20: 653-664.
63. Lannuzel, A., J. V. Barnier, C. Hery, V. T. Huynh, B. Guibert, F. Gray, J. D. Vincent, and M. Tardieu. 1997. Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons. Ann. Neurol. 42: 847-856.
64. Xiong, H., J. Boyle, M. Winkelbauer, Y. C. Zeng, J. Zheng, and H. E. Gendelman. 2000. IL-8 Inhibits Neuronal Long-term Potentiation: A Potential Mechanism for Cognitive Decline in HIV-1-Associated Dementia. In 7th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, San Francisco.
65. Xiong, H., Y. C. Zeng, T. Lewis, J. Zheng, Y. Persidsky, and H. E. Gendelman. 2000. HIV-1 infected mononuclear phagocyte secretory products affect neuronal physiology leading to cellular demise: relevance for HIV-1-associated dementia. J. Neurovirol. 6(Suppl 1): S14-S23. (Pubitemid 30342773)
66. Persidsky, Y., A. Ghorpade, J. Rasmussen, J. Limoges, X. J. Liu, M. Stins, M. Fiala, D. Way, K. S. Kim, M. H. Witte, et al. 1999. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155: 1599-1611.
67. Park, K. W., D. Y. Lee, E. H. Joe, S. U. Kim, and B. K. Jin. 2005. Neuroprotective role of microglia expressing interleukin-4. J. Neurosci. Res. 81: 397-402.
68. Clarke, R. M., A. Lyons, F. O'Connell, B. F. Deighan, C. E. Barry, N. G. Anyakoha, A. Nicolaou, and M. A. Lynch. 2008. A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J. Biol. Chem. 283: 1808-1817.
69. Brionne, T. C., I. Tesseur, E. Masliah, and T. Wyss-Coray. 2003. Loss of TGF-β 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40: 1133-1145.
70. Krieglstein, K., J. Strelau, A. Schober, A. Sullivan, and K. Unsicker. 2002. TGF-β and the regulation of neuron survival and death. J. Physiol. (Paris) 96: 25-30.
71. Terrado, J., D. Monnier, D. Perrelet, D. Vesin, S. Jemelin, W. A. Buurman, L. Mattenberger, B. King, A. C. Kato, and I. Garcia. 2000. Soluble TNF receptors partially protect injured motoneurons in the postnatal CNS. Eur. J. Neurosci. 12: 3443-3447.
72. Bartfai, T., M. Sanchez-Alavez, S. Andell-Jonsson, M. Schultzberg, A. Vezzani, E. Danielsson, and B. Conti. 2007. Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma. Ann. N. Y. Acad. Sci. 1113: 173-177.
73. Laske, C., P. Oschmann, J. Tofighi, S. B. Kuehne, H. Diehl, T. Bregenzer, J. Kraus, R. Bauer, N. Chatzimanolis, A. Kern, et al. 2001. Induction of sTNF-R1 and sTNF-R2 by interferon β-1b in correlation with clinical and MRI activity. Acta Neurol. Scand. 103: 105-113.
74. Góra-Kupilas, K., and J. Jośko. 2005. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol. 43: 31-39. (Pubitemid 40533190)
75. Barber, S. A., J. L. Uhrlaub, J. B. DeWitt, P. M. Tarwater, and M. C. Zink. 2004. Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am. J. Pathol. 164: 355-362.
76. Nguyen, D. G., H. Yin, Y. Zhou, K. C. Wolff, K. L. Kuhen, and J. S. Caldwell. 2007. Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening. Virology 362: 16-25.
77. Falsig, J., P. Pörzgen, J. Lotharius, and M. Leist. 2004. Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J. Immunol. 173: 2762-2770. (Pubitemid 39063138)
78. Müller, G. J., M. A. Geist, L. M. Veng, M. G. Willesen, F. F. Johansen, M. Leist, and E. Vaudano. 2006. A role for mixed lineage kinases in granule cell apoptosis induced by cytoskeletal disruption. J. Neurochem. 96: 1242-1252.
79. Harris, C., A. C. Maroney, and E. M. Johnson, Jr. 2002. Identification of JNK-dependent and -independent components of cerebellar granule neuron apoptosis. J. Neurochem. 83: 992-1001.
80. Otsuka, M., K. Goto, S. Tsuchiya, and Y. Aramaki. 2005. Phosphatidylserinespecific receptor contributes to TGF-β production in macrophages through a MAP kinase, ERK. Biol. Pharm. Bull. 28: 1707-1710.
81. Harper, S. J., and P. LoGrasso. 2001. Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell. Signal. 13: 299-310.
82. Mishra, S., J. P. Mishra, and A. Kumar. 2007. Activation of JNK-dependent pathway is required for HIV viral protein R-induced apoptosis in human monocytic cells: involvement of antiapoptotic BCL2 and c-IAP1 genes. J. Biol. Chem. 282: 4288-4300.
83. Dou, H., K. Birusingh, J. Faraci, S. Gorantla, L. Y. Poluektova, S. B. Maggirwar, S. Dewhurst, H. A. Gelbard, and H. E. Gendelman. 2003. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J. Neurosci. 23: 9162-9170.
84. Limoges, J., Y. Persidsky, L. Poluektova, J. Rasmussen, W. Ratanasuwan, M. Zelivyanskaia, D. McClernon, E. Lanier, and H. Gendelman. 2000. Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurologyo 54: 379-389. (Pubitemid 30078069)
85. Persidsky, Y., J. Limoges, J. Rasmussen, J. Zheng, A. Gearing, and H. E. Gendelman. 2001. Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis. J. Neuroimmunol. 114: 57-68.
86. Wang, L. H., E. M. Johnson, Jr., I. Shoulson, A. E. Lang, and D. Bozyczko-Coyne. 2008. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 71: 462-463, author reply 462-463.